ReviewProceedings of the National Academy of Sciences of the United States of America2015
Engineering opportunities in cancer immunotherapy.
Review in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 130 citations in OpenAlex.
- Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026Review
- Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.Molecular therapy. Nucleic acids · 2025Article
- Oral oncolytic magnetotactic bacteria elicit anti-colorectal tumor immunity and reprogram microbiota metabolism.Bioactive materials · 2025Article
- Innovations in Cancer Immunotherapy Drug Delivery Technologies: A Systematic Review.Journal of pharmacy & bioallied sciences · 2025Review
- Light-based technologies in immunotherapy: advances, mechanisms and applications.Immunotherapy · 2025Review
- Recent Updates on the Efficacy of Mitocans in Photo/Radio-therapy for Targeting Metabolism in Chemo/Radio-resistant Cancers: Nanotherapeutics.Current medicinal chemistry · 2025Review
- Focused shock waves and inertial cavitation release tumor-associated antigens from renal cell carcinoma.Ultrasonics sonochemistry · 2024Article
- A hybridized mechano-electroporation technique for efficient immune cell engineering.Journal of advanced research · 2024Article
- Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.Journal of hematology & oncology · 2023Review
- Three Dimensional Printing and Its Applications Focusing on Microneedles for Drug Delivery.Pharmaceutics · 2023Review
- Lymph node-targeting adjuvant/neoantigen-codelivering vaccines for combination glioblastoma radioimmunotherapy.Theranostics · 2023Article
- Review
- A Versatile Nanocarrier-Cubosomes, Characterization, and Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Impact of General Factors on Glioma Immunotherapy.Journal of clinical neurology (Seoul, Korea) · 2022Review
- Targeting regulated cell death in tumor nanomedicines.Theranostics · 2022Review
- Engineering Cancer/Testis Antigens With ReversibleFrontiers in oncology · 2022Article
- Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy.Acta pharmaceutica Sinica. B · 2022Review
- Cervical Cancer Immunotherapy: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Review
- The future of microfluidics in immune checkpoint blockade.Cancer gene therapy · 2021Review
- Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives.Journal of nanobiotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has great potential to treat cancer and prevent future relapse by activating the immune system to recognize and kill cancer cells. A variety of strategies are continuing to evolve in the laboratory and in the clinic, including therapeutic noncellular (vector-based or subunit) cancer vaccines, dendritic cell vaccines, engineered T cells, and immune checkpoint blockade. Despite their promise, much more research is needed to understand how and why certain cancers fail to respond to immunotherapy and to predict which therapeutic strategies, or combinations thereof, are most appropriate for each patient. Underlying these challenges are technological needs, including methods to rapidly and thoroughly characterize the immune microenvironment of tumors, predictive tools to screen potential therapies in patient-specific ways, and sensitive, information-rich assays that allow patient monitoring of immune responses, tumor regression, and tumor dissemination during and after therapy. The newly emerging field of immunoengineering is addressing some of these challenges, and there is ample opportunity for engineers to contribute their approaches and tools to further facilitate the clinical translation of immunotherapy. Here we highlight recent technological advances in the diagnosis, therapy, and monitoring of cancer in the context of immunotherapy, as well as ongoing challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.